Misplaced Pages

Fish oil, sold under the brand name Omegaven, is a fatty acid emulsion. It is used for total parenteral nutrition (feeding directly into a venous catheter), e.g. in short bowel syndrome. It is rich in omega-3 fatty acids.

Fish oil triglycerides was approved for use in the United States in July 2018, and is available to people on the US market by prescription effective November 2018.

In 2021, it was the 283rd most commonly prescribed medication in the United States, with more than 700,000 prescriptions.

Research

It has gained popularity in children in preference to the more commonly used intralipid after case reports that it reduced the risk of liver damage.

A 2007, study indicated that the use of Omegaven may be an appropriate intervention strategy for newborns with a very low birth weight, gastroschisis, and intestinal atresia.

A clinical trial exploring the use of fish oil as an adjunct to parenteral nutrition in surgical intensive care units at National Taiwan University Hospital completed in March 2007.

Although the use of fish oil triglycerides in children in the United States is experimental, the use of it in adults in Europe is less controversial. In European studies, fish oil triglycerides have been associated with a reduction in psoriasis, when contrasted to administration of omega-6 fatty acid Lipoven. Fish oil triglycerides have also been associated with reduced mortality and antibiotic use during hospital stays.

References

1. "Fat emulsion Use During Pregnancy". Drugs.com. 4 May 2020. Retrieved 12 May 2020.
2. ^ "Omegaven- fish oil injection, emulsion". DailyMed. 6 August 2018. Retrieved 13 May 2020.
3. "Drug Approval Package: Omegaven (fish oil triglycerides)". U.S. Food and Drug Administration (FDA). 24 August 2018. Retrieved 12 May 2020.
4. Research, Center for Drug Evaluation and. "Investigational New Drug (IND) Application - How to request Omegaven for Expanded Access Use". www.fda.gov. Retrieved 15 February 2019.
5. "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
6. "Fish Oil - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
7. Gura KM, Duggan CP, Collier SB, et al. (2006). "Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management". Pediatrics. 118 (1): e197–201. doi:10.1542/peds.2005-2662. PMID 16818533. S2CID 46567040.
8. Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK (2007). "Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease". Journal of Perinatology. 27 (5): 284–90. doi:10.1038/sj.jp.7211686. PMID 17344923. S2CID 12613845.
9. Clinical trial number NCT00172198 for "Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU." at ClinicalTrials.gov
10. A Doctor's Push For Drug Pits Him Against Its Maker at The Wall Street Journal
11. Mayser P, Grimm H, Grimminger F (2002). "n-3 fatty acids in psoriasis". Br. J. Nutr. 87. Suppl 1: S77–82. doi:10.1079/bjn2001459. PMID 11895157.
12. Heller AR, Rössler S, Litz RJ, et al. (2006). "Omega-3 fatty acids improve the diagnosis-related clinical outcome". Crit. Care Med. 34 (4): 972–9. doi:10.1097/01.CCM.0000206309.83570.45. PMID 16484909. S2CID 32537029.

External links

• Cooke, Robert (3 July 2006). "How fish oil may have saved babies' lives". The Boston Globe. Retrieved 22 August 2007.
• "The Right Kind of Oil" Archived 27 September 2007 at the Wayback Machine at Children's Hospital Boston
• Team on a Mission at Toronto Star
• Old Fashioned Lifeline Boston Globe 1/9/2009
• rockcenter.nbcnews.com: drug treatment omegaven that could save infants lives not yet approved by fda

• Medicine

• Drugs not assigned an ATC code
• Intensive care medicine
• Hepatology
• Gastroenterology
• Pediatrics
• Malnutrition
• Orphan drugs